Maja Primic Žakelj

TL;DR: The estimates of the burden of rare cancers in Europe, their time trends in incidence and survival, and information about centralisation of treatments in seven European countries are updated to help improve case management and survival.

TL;DR: Improvements in the diagnosis and registration of cancers over time could partly explain the observed increase in incidence, although some changes in underlying putative risk factors cannot be excluded.

TL;DR: Based on the analysis of three ‘field-practice’ cohorts collected in different settings, a prognostic score was defined and validated to classify patients into three groups with different long-term prognoses.